1. Our paper on lithium in drinking water and suicides in Switzerland was just accepted for publication. It is to our knowledge the first pre-registered study on this topic. We found a near perfect null-result.
2. Background: lithium is considered to be suicide protective in therapeutic doses and some are convinced it is THE drug in suicide prevention. However, with new evidence, appropriate statistical methods, and results for suic attempts, uncertainty remains
3. There are now ca 20 studies on lithium in drinking water and suicide rates. Overall, results support the suicide preventive powers of lithium bc higher lithium levels were associated with lower suicide rates. Some even suggested to add lithium to tap water.
4. However, as soon as the number of studies allowed the analysis of publication bias, such a bias was confirmed and accounting for missing studies lead to a much smaller and non-significant correlation of lithium and suicides.
5. Not surprising, because none of the studies were pre-registered. Some had absurdly high correlations (> 0.60) and the choice of confounders varied substantially. So we thought we should do a pre-registered study on the topic. Protocol here: osf.io/fn3u9
6. Thanks to a colleague who lives in Switzerland now, we got access to measures of lithium (> 4000 measues) from over 1000 municipalities and the suicides in these municipalities from 1981 to 2021. Thus, our study was well powered to detects small correlations.
7. We found null-findings for crude associations, after adjusting for confounders, using crude suicide rates and age-adjusted suicide rate ratios, and in models accounting for spatial dependency.
R-code and detailled analysis are on the OSF osf.io/gb2rk/
8. As happens ofen with inconvenient or null-findings, our manuscript was desk-rejected by several journals until one editor decided for review. One reviewer said “The anti-suicidal effect of lithium in bipolar, unipolar and some other psychiatric disorders is absolutely sure.”
9. He/she requested analysis separately for men and women and we did that, with similar null-findings among men and women.
10. I will provide the link to the publication later, when the paper is going online.
@threadreaderapp unroll
@ESYudkowsky Wouldn't this be better investigated with a random sample and checking lithium in the serum?
@SocDoneLeft Let's call it an informative graph ;-)
@XueFisher And on second thought, why should it vary over time? Lithium is basically washed out from rocks/soil, and this is a rather constant process. But appreciate your point!
@XueFisher A challenge was that suicides at the municipality level varied greatly, so choosing a restricted time-frame would have come with much noise.
@jt_kerwin But honestly, I am 52, and I am an existential psychotherapist and not on an academic track. I am simply too old to cheat in this, wasting precious lifetime just to come up with some results. No way
;-)
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1. Beitrag zu Antidepressiva (AD) im geschätzten Kulturradio Ö1 mit einer sympathischen Moderatorin die selber Erfahrungen mit Depressionen und AD hat.
Neben vielen guten Infos sind aber leider einige falsche oder veraltete Infos dabei. Ein 🧵 später oe1.orf.at/programm/20240…
2. "Psychologische" Absetzsymptome nach langer Einnahme. Falsch. Es gibt gute Hinweise dass problematische Entzugssymptome körperlicher Natur sind. Ja, man darf oder sogar soll dazu Entzugssymptome sagen.
3. Nicht erwähnt wurde: erst seit kurzem werden Absetzprobleme richtig beforscht und evidenzbasierte Ausschleichstrategien entwickelt. Lange wurde das verharmlost, auch in der Psychiatrie. Erst durch Engagement von Betroffenen (darunter Psychiater) änderte sich was.
1. Last year @NaudetFlorian and I pointed out severe problems in a review about lithium in drinking water and suicide. The problems are summarized in the thread below. So what happened afterwards?
2. To recap the most severe error: the author correlated suicide-rates w lithium-levels in international studies (each dot is a study). But this was a mix of suic-RATES (per 100,000) and suic-rate-RATIOS standardized to 1 in some studies or to 100 in others. You can't mix this!
3. Thus, the main result is completely meaningless. There are many more errors (e.g., using more than one study from the same region).
We wrote a letter and only yesterday I had access to what the editor said in an editorial where he commented on our letter. Take a breath:
A. A long thread in response to @royperlis, Harvard professor of psychiatry, who recently suggested that SSRIs should be available over the counter, as they “have repeatedly been shown to be safe and effective for treating major depression and anxiety disorders” 1
B. In the following, I will examine some of his arguments, as they are either in contradiction to the evidence or give a biased, uncritical summary on the evidence. I was blocked after saying that the harm/benefit ratio is problematic for the majority. Refs are available online.
C. Are SSRI’s save and effective? The scientific discussion ongoing 2–4. Theaverage efficacy (around 2 points on the Hamilton Depression Scale) in short-term clinical trials is below typical thresholds of clinical significance 5.
1/ Last year a study was published about escitalopram for GAD for children/adolescents, where it was concluded that ‘Escitalopram reduced anxiety symptoms and was well tolerated.’’. In our letter, we disagreed.
2/ mainly because only the primary outcome was just below the significance threshold, the effect size was likely not clinically meaningful, and there was a significantly higher risk for suicide ideation (not discussed at all in the paper) and adverse events with esc than placebo
3/ All 6 secondary outcomes were not significant and close to zero. Thus, the findings are just not compatible with the author’s conclusion.
Now the authors responded (paywalled) liebertpub.com/doi/full/10.10…
1/ Escitalopram now approved for generalized anxiety disorders for children & adolescents. FDA considers it as safe and effective for this new indication, based on a recent RCT. Let's have a look at this trial ->
2/ In the RCT, Strawn et al. (2023) concluded that “Escitalopram reduced anxiety symptoms and was well tolerated”. But this conclusion is not supported by the data presented. liebertpub.com/doi/full/10.10…
3/ Efficacy, according to the primary outcome, is small, with a standardized mean difference of 0.27 (not reported in paper).
1/ The "15% additional responders with antidepressants compared to placebo" message, based on the very good patient-level meta-analysis from 2022 deserves clarification. bmj.com/content/378/bm…
2/ In the analysis of >70,000 patients, the average drug-placebo difference was only 1.75 points on the Hamilton scale. Definitely not clinically significant. However, there is a deviation from the normal distribution, thus the average drug-placebo difference may be misleading
3/ Stone et al. provide analyses that may account for this problem by applying finite mixture modelling, where the non-normal distribution is deconstructed into a mix of separate distributions.